Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

Macrophage migration inhibitory factor (MIF) was originally identified in 1966 by Bloom and Bennett as a pro-inflammatory cytokine involved in the inhibition of macrophage motility. Since then, studies have investigated the functional contribution of this pro-inflammatory cytokine in several immune...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-10, Vol.12 (4), p.2247-2253
Main Authors: Kindt, Nadège, Journe, Fabrice, Laurent, Guy, Saussez, Sven
Format: Article
Language:English
Subjects:
Angiogenesis
Cancer
cancer therapy
Carcinogenesis
Care and treatment
Cell cycle
Cell growth
cell proliferation
Cellular proteins
Chemokines
Cytokines
Disease
Gastric cancer
Genetic aspects
Health aspects
Inflammatory diseases
invasion
Kinases
Liver cancer
Medical prognosis
Melanoma
Metastasis
migration inhibitory factor
Patients
Prostate
Review
Rodents
Signal transduction
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Macrophage migration inhibitory factor (MIF) was originally identified in 1966 by Bloom and Bennett as a pro-inflammatory cytokine involved in the inhibition of macrophage motility. Since then, studies have investigated the functional contribution of this pro-inflammatory cytokine in several immune diseases, including rheumatoid arthritis and lupus erythematous. Recently, MIF has been reported to be involved in a variety of neoplastic diseases. The present review discusses previous cancer research studies that have investigated the involvement of MIF in carcinogenesis, disease prognosis, tumor cell proliferation and invasion, and tumor-induced angiogenesis. Finally, potential therapeutic approaches based on the use of MIF antagonists and neutralizing antibodies are examined. The review concludes that MIF could be a good prognostic biomarker in several types of cancer, but also that the inhibition of MIF could represent a novel therapy against cancer.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.4929